Mexico - Delayed Quote MXN

Pfizer Inc. (PFE.MX)

548.50

-1.49

(-0.27%)

At close: January 31 at 2:44:04 PM CST

AbbVie earnings: Analyst weighs in on drug pipeline, HHS hearing

As its shares pop in Friday's session, pharmaceutical giant AbbVie Inc. (ABBV) posted a fourth quarter revenue beat and raised its long-term sales guidance for new drugs Skyrizi and Rinvoq by $4 billion. BMO Capital Markets managing director Evan Seigerman sits down with Seana Smith and Brad Smith on the Morning Brief to speak about AbbVie's drug research and product pipeline, especially as sales of immunosuppressant Humira fell dramatically by 49%. "They talk a lot about some of their efforts in oncology, some of their efforts in neuroscience. Yes, they had some disappointing news last year with their schizophrenia drug, but they are moving forward with other assets in Parkinson's and oncology." The senior biopharma research analyst also weighs in on Robert F. Kennedy Jr.'s secretary of the Department of Health and Human Services (HHS) confirmation hearing and how pharma stocks like Pfizer (PFE) and Merck (MRK) may be impacted: "There's been a lot of rhetoric over the past couple of days with the confirmation hearings. I've always said HHS is a very complicated organization. I'm still most focused on... the head of the FDA [Food and Drug Administration], potentially Martin McElroy. That's really important because that's kind of the critical agency for the biopharma sector." To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 13 hours ago

ABBV

PFE

MRK
Altria Is the New Dividend Leader in the S&P 500. Shares Yield Nearly 8%.

Altria became the index’s dividend leader on Thursday, after struggling Walgreens Boots Alliance suspended its payout that same day, citing an effort to improve its balance sheet. While Altria’s dividend payout ratio is high at about 80%—more than double that of the S&P 500—the company takes its dividend very seriously, having raised it in August for the 59th time in 55 years. Altria is a king among S&P dividend aristocrats.

Barrons.com 6 hours ago

MO

^GSPC

LYB
Pfizer resolves conservative challenge to diversity fellowship program

Pfizer has resolved a lawsuit by a conservative group that alleged that a fellowship program that the drugmaker established to boost the pipeline of Black, Latino and Native American people in leadership positions at the company unlawfully discriminated against white and Asian-American applicants. According to papers filed on Friday in Manhattan federal court, Pfizer will stop accepting new fellows and has already opened its program to applicants regardless of their race after being sued in 2022 by Do No Harm, an advocacy group opposed to diversity initiatives in medicine. The settlement came after the New York-based 2nd U.S. Circuit Court of Appeals on Jan. 10 reversed a judge's decision to dismiss the case and gave Do No Harm a new shot at establishing that it had the necessary legal standing to pursue the litigation.

Reuters 6 hours ago

PFE
Investing Action Plan: A Big Week For Biotechs, Pharma And Econ, Plus Amazon And Alphabet

The week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and Alphabet.

Investor's Business Daily 6 hours ago

AMZN

PLTR

GOOG
Stocks to watch next week: Amazon, Palantir, Disney, Novo Nordisk and AstraZeneca

Earnings preview of key companies reporting next week and what to look out for.

Yahoo Finance UK 14 hours ago

MDLZ

JCI

GOOG
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks 14 hours ago

PFE
Jim Cramer on Pfizer Inc. (PFE): ‘It’s Too Low To Sell’

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other stocks Jim Cramer recently talked about. Jim Cramer, the host of Mad Money, has been considering the uncertainty surrounding 2025 and the […]

Insider Monkey yesterday

PFE
Pfizer (PFE) is a Top-Ranked Momentum Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks yesterday

PFE
Exploring Analyst Estimates for Pfizer (PFE) Q4 Earnings, Beyond Revenue and EPS

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

Zacks yesterday

PFE
Pfizer (NYSE:PFE) Takes On Some Risk With Its Use Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Simply Wall St. yesterday

PFE
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings

Biotech stocks will need to brace for political "games" Wednesday as the Senate meets to potentially confirm RFK Jr. to lead HHS.

Investor's Business Daily 2 days ago

PFE

GLAXF

GSK
Is Pfizer Inc. (PFE) the Safe Stock to Buy for the Long Term in 2025?

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other safe stocks to buy for the long term in 2025. The US stock market is often regarded as one of […]

Insider Monkey 3 days ago

PFE

^GSPC
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

In the latest trading session, Pfizer (PFE) closed at $26.75, marking a -0.41% move from the previous day.

Zacks 3 days ago

PFE

^GSPC
Drugmakers Show Restraint on Price Increases in New Trump Era

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a median 4% at the start of this year. The modest size of the annual increases could help companies avoid criticism of gouging from President Trump while seeking his administration’s support for such priorities as taking aim at the rebates given to middlemen and altering a federal program providing discounts to certain hospitals. Last year’s median price increase was 4.5%.

The Wall Street Journal 3 days ago

PFE

AMGN

UTHR
Pfizer Inc. (PFE): Is This Healthcare Stock A Good Buy?

We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other healthcare stocks. Healthcare stocks are widely considered a cornerstone of a retirement portfolio due to their resilience, long-term growth potential, and ability […]

Insider Monkey 3 days ago

PFE
PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor

A Bloomberg article suggests activist investor Starboard cut Pfizer some slack by not nominating any director on the company's board this year.

Zacks 3 days ago

PFE

CSTL
Here's How to Play Pfizer Stock Before Q4 Earnings Release

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.

Zacks 3 days ago

PFE
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium

NEW YORK, January 28, 2025--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February 13-15 in San Francisco, California. Data from more than 20 company-sponsored, investigator-sponsored, and collaborative research abstracts, including five oral presentations, highlight advancements in developing new standards of care within prostate and bladder

Business Wire 3 days ago

PFE
I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.

When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to the S&P 500 over holding periods of 20+ years. Companies that maintain above-average dividend yields over extended periods typically share key characteristics. AbbVie Inc. (NYSE: ABBV) represents my top holding in the healthcare sector.

Motley Fool 3 days ago

PM

ABBV

PFE
Pfizer Jumps After Avoiding Proxy Fight With Activist Investor Starboard — For Now

Pfizer stock bounded off its 50-day line on Monday after avoiding a battle with activist investor Starboard Value — for now.

Investor's Business Daily 4 days ago

PFE

Performance Overview

Return	PFE.MX	S&P 500
YTD	+0.63%	+2.26%
1-Year	+18.34%	+22.65%
3-Year	-51.02%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pfizer Inc. (PFE.MX)

AbbVie earnings: Analyst weighs in on drug pipeline, HHS hearing

Altria Is the New Dividend Leader in the S&P 500. Shares Yield Nearly 8%.

Pfizer resolves conservative challenge to diversity fellowship program

Investing Action Plan: A Big Week For Biotechs, Pharma And Econ, Plus Amazon And Alphabet

Stocks to watch next week: Amazon, Palantir, Disney, Novo Nordisk and AstraZeneca

Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know

Jim Cramer on Pfizer Inc. (PFE): ‘It’s Too Low To Sell’

Pfizer (PFE) is a Top-Ranked Momentum Stock: Should You Buy?

Exploring Analyst Estimates for Pfizer (PFE) Q4 Earnings, Beyond Revenue and EPS

Pfizer (NYSE:PFE) Takes On Some Risk With Its Use Of Debt

The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings

Is Pfizer Inc. (PFE) the Safe Stock to Buy for the Long Term in 2025?

Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

Drugmakers Show Restraint on Price Increases in New Trump Era

Pfizer Inc. (PFE): Is This Healthcare Stock A Good Buy?

PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor

Here's How to Play Pfizer Stock Before Q4 Earnings Release

Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium

I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.

Pfizer Jumps After Avoiding Proxy Fight With Activist Investor Starboard — For Now

Performance Overview